RxDoctor Payments Data

Ryan Jenson, DPM

Foot & Ankle Surgery · Kansas City, MONPI 1225690068

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,069 of the $16,506 with a category attached, or 73.1%. It is spread thinly across 56 manufacturers, the largest accounting for just 14.4%. Reporting peaked in 2024 at $5,982 and has fallen 59.3% since, to $2,437 in 2025.

$16,506in general payments, 2019–2025

Across 258 payments — averaging $63.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orthofix Medical, Inc.$2K
  • Medline Industries LP$2K
  • Mimedx Group, Inc.$2K
  • Organogenesis Inc.$1K
  • Stryker$1K
  • Paragon 28, Inc.$1K
  • plus $8K from 50 others

What the payments were for

  • Speaking & faculty fees$100%
  • Travel & lodging$4,42827%
  • Food & beverage$12,06973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,506 in reported general payments places this provider in the 75th percentile of 163 foot & ankle surgery providers in Missouri.

See all foot & ankle surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$145,814
Medicare patients
445
Services billed
3,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole12$17,098
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$371
Cephalexin25$242
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$213
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$208
Mupirocin23$168
Meloxicam63$148
Terbinafine Hcl12$145
Methylprednisolone22$136
Doxycycline Hyclate16$103
Gabapentin12$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$23$17,09812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 163 foot & ankle surgery providers in Missouri.

Other foot & ankle surgery in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →